Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31496147 | 0.89 | DGAT1 (0.56) | DGAT1GPR119CYP11B2 | |
| SCHEMBL20129266 | 0.87 | DGAT1 (0.48) | DGAT1GPR119P2RX3P2RX2RORC | |
| SCHEMBL31401120 | 0.85 | DGAT1 (0.57) | DGAT1GPR119RORCPIK3CD | |
| SCHEMBL15525341 | 0.85 | DGAT1 (0.57) | DGAT1GPR119RORCPIK3CD | |
| SCHEMBL23850304 | 0.85 | HSD11B1 (0.47) | GPR119P2RX3P2RX2ABHD6HSD11B1 | |
| SCHEMBL30427128 | 0.83 | GPR119 (0.66) | DGAT1GPR119 | |
| SCHEMBL940648 | 0.83 | GPR119 (0.66) | DGAT1GPR119 | |
| SCHEMBL31548232 | 0.83 | KRAS (0.41) | DGAT1GPR119P2RX3P2RX2RORC | |
| SCHEMBL29799526 | 0.82 | RORC (0.47) | GPR119P2RX3P2RX2RORCABHD6 | |
| SCHEMBL20129223 | 0.81 | DGAT1 (0.43) | DGAT1GPR119P2RX3P2RX2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DGAT1 4519/4885GPR119 3791/4885P2RX3 4712/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | DGAT1 4651/4885GPR119 3741/4885P2RX3 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.